Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Hits New 1-Year High – What’s Next?

Bayer Aktiengesellschaft (OTCMKTS:BAYRYGet Free Report)’s share price hit a new 52-week high during trading on Monday . The stock traded as high as $8.8275 and last traded at $8.80, with a volume of 138652 shares. The stock had previously closed at $7.94.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Zacks Research lowered shares of Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 3rd. Wall Street Zen raised shares of Bayer Aktiengesellschaft from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy”.

Read Our Latest Stock Analysis on BAYRY

Bayer Aktiengesellschaft Price Performance

The company has a market cap of $34.78 billion, a PE ratio of -9.12, a price-to-earnings-growth ratio of 3.62 and a beta of 0.84. The stock has a fifty day moving average price of $7.98 and a 200-day moving average price of $7.80. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.13 and a quick ratio of 0.73.

About Bayer Aktiengesellschaft

(Get Free Report)

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.

See Also

Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.